世界の医薬品産業：競合情勢 (2023年)

当レポートでは、世界の医薬品産業の競合情勢を調査し、主要企業の市場ランキング、上位医薬品、製薬企業上位50社の企業プロファイル、革新的な製品と技術、動向と市場力学、競合情報、地域動向などをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー

第2章 市場概要

• 概要
• イノベーションプロセスに関与するステークホルダー
• 将来の展望
• PESTEL分析
• ポーターのファイブフォース分析
• サプライチェーン分析
• 原材料調達
• 医薬品製造
• 品質管理とコンプライアンス
• 分布
• 規制当局の承認と価格制約
• 営業とマーケティング
• リバースロジスティクスと返品

第3章 市場力学

• 市場力学
• 市場促進要因
• 医療費の増加
• 希少疾患と希少疾病用医薬品への焦点
• 慢性疾患の増加と人口の高齢化
• 市場抑制要因
• 厳しい規制上の懸念
• 独占性の喪失とジェネリック化
• 腫瘍学専門家の不足
• 市場機会
• 健康の公平性とアクセシビリティに焦点を当てる
• 腫瘍におけるAI
• 新興市場
• 市場の課題
• 価格圧力と市場アクセス
• 環境への影響と持続可能性
• 偽造医薬品

第4章 規制状況

• 規制の枠組み
• バイオ医薬品の規制制度
• 米国
• 欧州
• 日本
• 医薬品規制制度
• 米国
• EUの承認プロセス
• 日本の承認プロセス
• インドの承認プロセス
• ブラジルの承認プロセス
• GMPコンプライアンス
• 製造施設の登録
• 医薬品の登録とリスティング
• 現地代理人要件
• 米国代理人の責任

第5章 新興技術と開発

• 新興技術
• AIと機械学習 (ML)
• ナノテクノロジー
• 3Dプリント
• 特許分析
• サマリー

第6章 医薬品業界における持続可能性：ESGの観点

• 医薬品業界における持続可能性
• 環境
• 社会
• ガバナンス
• ESGデータの理解
• BCCによる総論

第7章 競合情報

• 概要
• 製薬会社の世界の市場シェア
• 大手製薬会社の戦略
• 流通網

第8章 付録

• 調査手法
• 略語
• 出典
• 企業プロファイル
• ABBOTT
• ABBVIE INC.
• ALNYLAM PHARMACEUTICALS INC.
• AMGEN INC.
• ARGENX
• ASTELLAS PHARMA INC.
• ASTRAZENECA
• AUROBINDO PHARMA LTD.
• BAUSCH HEALTH COMPANIES INC.
• BAXTER
• BAYER AG
• BIOCON
• BIOGEN
• BIOMARIN
• BIONTECH SE
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• CHUGAI PHARMACEUTICAL CO. LTD.
• CSL
• CSPC PHARMACEUTICAL GROUP LTD.
• DAIICHI SANKYO CO. LTD.
• DIVI'S LABORATORIES LTD.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• GALDERMA
• GILEAD SCIENCES INC.
• GRIFOLS S.A.
• GSK PLC.
• H. LUNDBECK A/S
• INCYTE
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON SERVICES INC.
• LES LABORATOIRES SERVIER
• LILLY
• MERCK & CO. INC.
• MERCK KGAA
• MODERNA INC.
• NEUROCRINE BIOSCIENCES INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• OTSUKA HOLDINGS CO. LTD.
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• SINO BIOPHARMACEUTICAL CO. LTD.
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VERTEX PHARMACEUTICALS INC.
• VIATRIS INC.
• 新興企業

List of Tables

• Summary Table : Global Market for Pharmaceutical Drugs, by Region, Through 2029
• Table 1 : Global Health Expenditures, by Country, 2022
• Table 2 : Global Incidence of All Cancers, by WHO Region, 2022-2050
• Table 3 : Pharmaceutical Drug Patents Granted, by Leading Applicant, 2023
• Table 4 : Pharmaceutical Drug Patents Granted, by Assignee Country/Region, January 2023-January 2025
• Table 5 : ESG Rankings for Pharmaceutical Companies
• Table 6 : Global Market Shares of Pharmaceutical Drugs, by Company, 2023
• Table 7 : Best-Selling Pharmaceuticals, 2023
• Table 8 : Total Revenue, Pharmaceutical Revenue, R&D Expenditure and Percentage of R&D in Revenue, by Drug Manufacturer, 2023
• Table 9 : Abbreviations Used in this Report
• Table 10 : Information Sources Used for this Report
• Table 11 : Abbott: Company Snapshot
• Table 12 : Abbott: Financial Performance, FY 2022 and 2023
• Table 13 : Abbott: Product Portfolio
• Table 14 : AbbVie Inc.: Company Snapshot
• Table 15 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 16 : AbbVie Inc.: Product Portfolio
• Table 17 : AbbVie Inc.: News/Key Developments, 2023-2025
• Table 18 : Alnylam Pharmaceuticals Inc.: Company Snapshot
• Table 19 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 20 : Alnylam Pharmaceuticals Inc.: Product Portfolio
• Table 21 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
• Table 22 : Amgen Inc.: Company Snapshot
• Table 23 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 24 : Amgen Inc.: Product Portfolio
• Table 25 : Amgen Inc.: News/Key Developments, 2023-2025
• Table 26 : Argenx: Company Snapshot
• Table 27 : Argenx: Financial Performance, FY 2022 and 2023
• Table 28 : Argenx: Product Portfolio
• Table 29 : Argenx: News/Key Developments, 2023 and 2024
• Table 30 : Astellas Pharma Inc.: Company Snapshot
• Table 31 : Astellas Pharma Inc: Financial Performance, FY 2022 and 2023
• Table 32 : Astellas Pharma Inc.: Product Portfolio
• Table 33 : Astellas Pharma Inc.: News/Key Developments, 2023-2025
• Table 34 : AstraZeneca: Company Snapshot
• Table 35 : AstraZeneca: Financial Performance, FY 2022 and 2023
• Table 36 : AstraZeneca: Product Portfolio
• Table 37 : AstraZeneca: News/Recent Developments, 2023-2025
• Table 38 : Aurobindo Pharma Ltd.: Company Snapshot
• Table 39 : Aurobindo Pharma Ltd.: Financial Performance, FY 2022 and 2023
• Table 40 : Aurobindo Pharma Ltd.: Product Portfolio
• Table 41 : Aurobindo Pharma Ltd.: News/Key Developments, 2023 and 2024
• Table 42 : Bausch Health Companies Inc.: Company Snapshot
• Table 43 : Bausch Health Companies Inc.: Financial Performance, FY 2022 and 2023
• Table 44 : Bausch Health Companies Inc.: Product Portfolio
• Table 45 : Bausch Health Companies Inc.: News/Key Developments, 2023
• Table 46 : Baxter: Company Snapshot
• Table 47 : Baxter: Financial Performance, FY 2022 and 2023
• Table 48 : Baxter: Product Portfolio
• Table 49 : Baxter: News/Key Developments, 2023 and 2024
• Table 50 : Bayer AG: Company Snapshot
• Table 51 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 52 : Bayer AG: Product Portfolio
• Table 53 : Bayer AG: News/Key Developments, 2023-2025
• Table 54 : Biocon: Company Snapshot
• Table 55 : Biocon: Financial Performance, FY 2022 and 2023
• Table 56 : Biocon: Product Portfolio
• Table 57 : Biocon: News/Key Developments, 2023-2024
• Table 58 : Biogen: Company Snapshot
• Table 59 : Biogen: Financial Performance, FY 2022 and 2023
• Table 60 : Biogen: Product Portfolio
• Table 61 : Biogen: News/Key Developments, 2023-2025
• Table 62 : BioMarin: Company Snapshot
• Table 63 : BioMarin: Financial Performance, FY 2022 and 2023
• Table 64 : BioMarin: Product Portfolio
• Table 65 : BioMarin: News/Key Developments, 2021-2024
• Table 66 : BioNTech SE: Company Snapshot
• Table 67 : BioNTech SE: Financial Performance, FY 2022 and 2023
• Table 68 : BioNTech SE: Product Portfolio
• Table 69 : BioNTech: News/Key Developments, 2023-2025
• Table 70 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 71 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
• Table 72 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 73 : Boehringer Ingelheim International GmbH: News/Key Developments, 2023-2025
• Table 74 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 75 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 76 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 77 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
• Table 78 : Chugai Pharmaceutical Co. Ltd.: Company Snapshot
• Table 79 : Chugai Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 80 : Chugai Pharmaceutical Co. Ltd.: Product Portfolio
• Table 81 : Chugai Pharmaceutical Co. Ltd: News/Key Developments, 2023-2025
• Table 82 : CSL: Company Snapshot
• Table 83 : CSL: Financial Performance, FY 2022 and 2023
• Table 84 : CSL: Product Portfolio
• Table 85 : CSL: News/Key Developments, 2023-2025
• Table 86 : CSPC Pharmaceutical Group Ltd.: Company Snapshot
• Table 87 : CSPC Pharmaceutical Group Ltd.: Financial Performance, FY 2022 and 2023
• Table 88 : CSPC Pharmaceutical Group Ltd.: Product Portfolio
• Table 89 : CSPC Pharmaceutical Group Ltd.: News/Key Developments, 2024
• Table 90 : Daiichi Sankyo Co. Ltd.: Company Snapshot
• Table 91 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 92 : Daiichi Sankyo Co. Ltd.: Product Portfolio
• Table 93 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2025
• Table 94 : Divi's Laboratories Ltd.: Company Snapshot
• Table 95 : Divi's Laboratories Ltd.: Financial Performance, FY 2022 and 2023
• Table 96 : Divi's Laboratories Ltd.: Product Portfolio
• Table 97 : Eisai Co. Ltd.: Company Snapshot
• Table 98 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 99 : Eisai Co. Ltd.: Product Portfolio
• Table 100 : Eisai Co. Ltd.: News/Recent Developments, 2023-2025
• Table 101 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 102 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 103 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 104 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
• Table 105 : Galderma: Company Snapshot
• Table 106 : Galderma: Financial Performance, FY 2022 and 2023
• Table 107 : Galderma: Product Portfolio
• Table 108 : Galderma: News/Key Developments, 2024
• Table 109 : Gilead Sciences Inc.: Company Snapshot
• Table 110 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
• Table 111 : Gilead Sciences Inc.: Product Portfolio
• Table 112 : Gilead Sciences Inc.: News/Key Developments, 2023-2025
• Table 113 : Grifols S.A: Company Snapshot
• Table 114 : Grifols S.A.: Financial Performance, FY 2022 and 2023
• Table 115 : Grifols S.A: Product Portfolio
• Table 116 : Grifols S.A: News/Key Developments, 2023-2025
• Table 117 : GSK plc.: Company Snapshot
• Table 118 : GSK plc.: Financial Performance, FY 2022 and 2023
• Table 119 : GSK plc.: Product Portfolio
• Table 120 : GSK plc.: News/Key Developments, 2023-2025
• Table 121 : H. Lundbeck A/S: Company Snapshot
• Table 122 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
• Table 123 : H. Lundbeck A/S: Product Portfolio
• Table 124 : H. Lundbeck A/S: News/Key Developments, 2022-2024
• Table 125 : Incyte: Company Snapshot
• Table 126 : Incyte: Financial Performance, FY 2022 and 2023
• Table 127 : Incyte: Product Portfolio
• Table 128 : Incyte: News/Key Developments, 2023-2025
• Table 129 : Jazz Pharmaceuticals Inc.: Company Snapshot
• Table 130 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 131 : Jazz Pharmaceuticals Inc.: Product Portfolio
• Table 132 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
• Table 133 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 134 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
• Table 135 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 136 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
• Table 137 : Les Laboratoires Servier: Company Snapshot
• Table 138 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
• Table 139 : Les Laboratoires Servier: Product Portfolio
• Table 140 : Les Laboratoires Servier: News/Key Developments, 2023-2025
• Table 141 : Lilly: Company Snapshot
• Table 142 : Lilly: Financial Performance, FY 2022 and 2023
• Table 143 : Lilly: Product Portfolio
• Table 144 : Lilly: News/Key Developments, 2022-2025
• Table 145 : Merck & Co. Inc.: Company Snapshot
• Table 146 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
• Table 147 : Merck & Co. Inc.: Product Portfolio
• Table 148 : Merck & Co. Inc.: News/Key Developments, 2021-2024
• Table 149 : Merck KGaA: Company Snapshot
• Table 150 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 151 : Merck KGaA: Product Portfolio
• Table 152 : Merck KGaA: News/Key Developments, 2023-2025
• Table 153 : Moderna Inc.: Company Snapshot
• Table 154 : Moderna Inc.: Financial Performance, FY 2022 and 2023
• Table 155 : Moderna Inc.: Product Portfolio
• Table 156 : Moderna Inc.: News/Key Developments, 2023 and 2024
• Table 157 : Neurocrine Biosciences Inc: Company Snapshot
• Table 158 : Neurocrine Biosciences Inc: Financial Performance, FY 2022 and 2023
• Table 159 : Neurocrine Biosciences Inc: Product Portfolio
• Table 160 : Neurocrine Biosciences Inc: News/Key Developments, 2023-2025
• Table 161 : Novartis AG: Company Snapshot
• Table 162 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 163 : Novartis AG: Product Portfolio
• Table 164 : Novartis AG: News/Key Developments, 2022-2024
• Table 165 : Novo Nordisk A/S: Company Snapshot
• Table 166 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
• Table 167 : Novo Nordisk A/S: Product Portfolio
• Table 168 : Novo Nordisk A/S: News/Key Developments, 2023-2025
• Table 169 : Otsuka Holdings Co. Ltd.: Company Snapshot
• Table 170 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 171 : Otsuka Holdings Co. Ltd.: Product Portfolio
• Table 172 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
• Table 173 : Pfizer Inc.: Company Snapshot
• Table 174 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 175 : Pfizer Inc.: Product Portfolio
• Table 176 : Pfizer Inc.: News/Key Developments, 2023 and 2024
• Table 177 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 178 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 179 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 180 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
• Table 181 : Sanofi: Company Snapshot
• Table 182 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 183 : Sanofi: Product Portfolio
• Table 184 : Sanofi: News/Key Developments, 2022-2025
• Table 185 : Sino Biopharmaceutical Co. Ltd.: Company Snapshot
• Table 186 : Sino Biopharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 187 : Sino Biopharmaceutical Co. Ltd.: Product Portfolio
• Table 188 : Sino Biopharmaceutical Co. Ltd.: News/Key Developments, 2023-2025
• Table 189 : Sun Pharmaceutical Industries Ltd.: Company Snapshot
• Table 190 : Sun Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
• Table 191 : Sun Pharmaceutical Industries Ltd.: Product Portfolio
• Table 192 : Sun Pharmaceutical Industries Ltd.: News/Key Developments, 2022-2024
• Table 193 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 194 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 195 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 196 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
• Table 197 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 198 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
• Table 199 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 200 : Vertex Pharmaceuticals Inc.: Company Snapshot
• Table 201 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 202 : Vertex Pharmaceuticals Inc.: Product Portfolio
• Table 203 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2022-2025
• Table 204 : Viatris Inc.: Company Snapshot
• Table 205 : Viatris Inc.: Financial Performance, FY 2022 and 2023
• Table 206 : Viatris Inc.: Product Portfolio
• Table 207 : Viatris Inc.: News/Key Developments, 2023 and 2024
• Table 208 : Few Emerging Players in the Market

List of Figures

• Summary Figure : Global Market Shares of Pharmaceutical Drugs, by Region, 2023
• Figure 1 : Supply Chain of the Pharmaceutical Drugs Industry
• Figure 2 : Pharmaceutical Drug Industry Market Dynamics
• Figure 3 : Trends and Emerging Technologies in the Pharmaceutical Drug Industry
• Figure 4 : Global Market Shares of Leading Pharmaceutical Drug Companies, 2023
• Figure 5 : Abbott: Revenue Share, by Business Unit, FY 2023
• Figure 6 : Abbott: Revenue Share, by Country/Region, FY 2023
• Figure 7 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 8 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 9 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 10 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 11 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 12 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 13 : Argenx: Revenue Share, by Country/Region, FY 2023
• Figure 14 : Astellas Pharma Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 15 : Astellas Pharma Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 16 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
• Figure 17 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
• Figure 18 : Aurobindo Pharma Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 19 : Aurobindo Pharma Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 20 : Bausch Health Companies Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 21 : Bausch Health Companies Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 22 : Baxter: Revenue Share, by Business Unit, FY 2023
• Figure 23 : Baxter: Revenue Share, by Country/Region, FY 2023
• Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023
• Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023
• Figure 26 : Biocon: Revenue Share, by Business Unit, FY 2023
• Figure 27 : Biogen: Revenue Share, by Business Unit, FY 2023
• Figure 28 : Biogen: Revenue Share, by Country/Region, FY 2023
• Figure 29 : BioMarin: Revenue Share, by Business Unit, FY 2023
• Figure 30 : BioMarin: Revenue Share, by Country/Region, FY 2023
• Figure 31 : BioNTech SE: Revenue Share, by Business Unit, FY 2023
• Figure 32 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
• Figure 33 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
• Figure 34 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
• Figure 35 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
• Figure 36 : Chugai Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
• Figure 37 : CSL: Revenue Share, by Business Unit, FY 2023
• Figure 38 : CSL: Revenue Share, by Region, FY 2023
• Figure 39 : CSPC Pharmaceutical Group Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 40 : CSPC Pharmaceutical Group Ltd.: Revenue Share, by Region, FY 2023
• Figure 41 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 42 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Region, FY 2023
• Figure 43 : Divi's Laboratories Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 44 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 45 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023
• Figure 46 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 48 : Galderma: Revenue Share, by Business Unit, FY 2023
• Figure 49 : Galderma: Revenue Share, by Country/Region, FY 2023
• Figure 50 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 51 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 52 : Grifols S.A: Revenue Share, by Business Unit, FY 2023
• Figure 53 : Grifols S.A.: Revenue Share, by Region, FY 2023
• Figure 54 : GSK plc.: Revenue Share, by Business Unit, FY 2023
• Figure 55 : GSK plc.: Revenue Share, by Country/Region, FY 2023
• Figure 56 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023
• Figure 57 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023
• Figure 58 : Incyte: Revenue Share, by Business Unit, FY 2023
• Figure 59 : Jazz Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 60 : Jazz Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 61 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 62 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 63 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023
• Figure 64 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023
• Figure 65 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 66 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 67 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 68 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 69 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
• Figure 70 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
• Figure 71 : Moderna Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 72 : Neurocrine Biosciences Inc: Revenue Share, by Business Unit, FY 2023
• Figure 73 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 74 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 75 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
• Figure 76 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
• Figure 77 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 78 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 79 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 80 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 81 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 82 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 83 : Sanofi: Revenue Share, by Business Unit, FY 2023
• Figure 84 : Sanofi: Revenue Share, by Country/Region, FY 2023
• Figure 85 : Sino Biopharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 86 : Sino Biopharmaceutical Co. Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 87 : Sun Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 88 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 89 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
• Figure 90 : Teva Pharmaceutical Industries Ltd: Revenue Share, by Business Unit, FY 2023
• Figure 91 : Teva Pharmaceutical Industries Ltd: Revenue Share, by Country/Region, FY 2023
• Figure 92 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 93 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 94 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 95 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023

This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Report Scope

This research report analyzes the global market for pharmaceutical drugs and its competitive landscape through 2029. It covers leading manufacturers of pharmaceutical drugs and the companies providing pharmaceutical services to biopharma and pharmaceutical firms), competitive intelligence and technological advances. The analysis includes recent developments in the product portfolios of major companies, as well as market share and rankings. The regulatory landscape analysis focuses on recent regulations in the U.S., Europe, and Japan. BCC Research estimated market size data for 2023 (base year) and forecast values for 2024 through the end of 2029. This report also examines drivers, restraints, and opportunities in the global market.

Report Includes

• 57 data tables and 152 additional tables
• Evaluation of the current and future market potential of the pharmaceutical industry, featuring a look at the competitive landscape of the 50 leading pharmaceutical manufacturers
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2021-2024, and projected CAGRs through 2029
• Discussion of the opportunities in the pharmaceutical industry, along with an evaluation of the competitive environment, regulatory landscape, and technological trends and advances
• A look at the regulatory and pricing scenarios in the global market, with an emphasis on recently enacted regulations in the U.S., Europe and Japan
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of patent activity, including key granted and published patents
• Descriptive company profiles of the leading pharma manufacturers, including Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., and F. Hoffmann La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Stakeholders Involved in the Innovation Process
• Future Perspectives
• PESTEL Analysis
• Porter's Five Forces Analysis
• Supply Chain Analysis
• Raw Materials Sourcing
• Drug Manufacturing
• QC and Compliance
• Distribution
• Regulatory Approval and Pricing Constraints
• Sales and Marketing
• Reverse Logistics and Returns

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Healthcare Expenditures
• Focus on Rare Diseases and Orphan Drugs
• Increasing Prevalence of Chronic Diseases and Aging Populations
• Market Restraints
• Stringent Regulatory Concerns
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals
• Market Opportunities
• Focus on Health Equity and Accessibility
• AI in Oncology
• Emerging Markets
• Market Challenges
• Price Pressures and Market Access
• Environmental Impact and Sustainability
• Counterfeit Drugs

Chapter 4 Regulatory Landscape

• Regulatory Framework
• Regulatory Systems for Biopharmaceuticals
• U.S.
• Europe
• Japan
• Regulatory Systems for Pharmaceuticals
• U.S.
• EU Approval Process
• Japan Approval Process
• India Approval Process
• Brazil Approval Process
• GMP Compliance
• Establishment Registration
• Drug Registration and Listing
• Local Agent Requirements
• Responsibilities of the U.S. Agent

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Artificial Intelligence (AI) and Machine Learning (ML)
• Nanotechnology
• 3D Printing
• Patent Analysis
• Takeaways

Chapter 6 Sustainability in the Pharmaceutical Drug Industry: An ESG Perspective

• Sustainability in the Pharmaceutical Drugs Industry
• Environmental
• Social
• Governance
• Understanding ESG Data
• Concluding Remarks from BCC Research

Chapter 7 Competitive Intelligence

• Overview
• Global Market Shares of Pharmaceutical Drug Companies
• Strategies of Major Pharmaceutical Drug Manufacturers
• Distribution Networks

Chapter 8 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• ABBVIE INC.
• ALNYLAM PHARMACEUTICALS INC.
• AMGEN INC.
• ARGENX
• ASTELLAS PHARMA INC.
• ASTRAZENECA
• AUROBINDO PHARMA LTD.
• BAUSCH HEALTH COMPANIES INC.
• BAXTER
• BAYER AG
• BIOCON
• BIOGEN
• BIOMARIN
• BIONTECH SE
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• CHUGAI PHARMACEUTICAL CO. LTD.
• CSL
• CSPC PHARMACEUTICAL GROUP LTD.
• DAIICHI SANKYO CO. LTD.
• DIVI'S LABORATORIES LTD.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• GALDERMA
• GILEAD SCIENCES INC.
• GRIFOLS S.A.
• GSK PLC.
• H. LUNDBECK A/S
• INCYTE
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON SERVICES INC.
• LES LABORATOIRES SERVIER
• LILLY
• MERCK & CO. INC.
• MERCK KGAA
• MODERNA INC.
• NEUROCRINE BIOSCIENCES INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• OTSUKA HOLDINGS CO. LTD.
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• SINO BIOPHARMACEUTICAL CO. LTD.
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VERTEX PHARMACEUTICALS INC.
• VIATRIS INC.
• Emerging Players in the Market